Methimazole pharmacology in the rat: studies using a newly developed radioimmunoassay for methimazole.

Methimazole [1-methyl-2-mercaptoimidazole (MMI)] was given to normal male rats in their drinking water in concentrations ranging from 0.0001-0.05% for either 1 week or 1 month. Serum MMI levels in the rats ranged from 0.008-19.6 micrograms/ml, and were similar after 1 week and 1 month of treatment. Serum MMI was linearly related to the MMI concentration in the drinking water (r = 0.98, P less than 0.001). In contrast, intrathyroid MMI content plateaued with increasing MMI concentrations in the water, and was linearly related to the logarithm of the MMI concentration. At the highest MMI concentration (0.05%), thyroid MMI contents were similar in the 1-week and 1-month groups (approximately 1 X 10(-4) M). Surprisingly, at lower MMI concentrations, thyroid MMI content was significantly higher in the 1-week group than the 1-month group. Thyroid function was inhibited by MMI with similar depression of serum T4 or T3 after 1 week or 1 month of MMI treatment. Although the MMI concentration for 50% suppression of thyroid PBI was 0.003% in both groups, thyroid MMI content at this MMI concentration was 97 microM after 1 week but only 15 microM after 1 month. The continued thyroid-inhibiting activity of MMI at 1 month, despite a striking decrease in thyroid MMI content, may relate to intrathyroid iodide depletion, which was more severe after 1 month (thyroid 127I = 40 microM) than after 1 week (thyroid 127I = 140 microM) or in controls (470 microM). Rats were given 0.05% MMI for either 1 week or 1 month, and the drug was then withdrawn. In the 1-week group, serum MMI disappeared biexponentially, with a rapidly declining phase (t1/2 = 3.2 h) and a second, slower disappearance phase (t1/2 = 47.7 h). Similar findings were noted after 1 month of treatment. The disappearance of thyroid MMI was also biexponential after 1 week, but this variable could not be evaluated after 1 month because thyroid MMI fell rapidly to undetectable levels. There was a highly significant correlation in the 1-week group between the disappearance of MMI from the thyroid and the recovery of thyroid function as assessed by thyroid PBI (r = 0.81, P less than 0.01). Despite the very rapid disappearance of MMI from the thyroid after 1 month of treatment, the recovery time of thyroid PBI was significantly longer than after 1 week of treatment (2.1 days vs. 1.4 days for 50% recovery, P less than 0.01).(ABSTRACT TRUNCATED AT 400 WORDS)

[1]  R. Jansson,et al.  Intrathyroidal concentrations of methimazole in patients with Graves' disease. , 1983, The Journal of clinical endocrinology and metabolism.

[2]  E. Sellers,et al.  Determination of free propylthiouracil clearance and single sample prediction of steady state , 1982, The Journal of pharmacy and pharmacology.

[3]  J. Hansen,et al.  Clinical Pharmacokinetics of Antithyroid Drugs , 1981, Clinical pharmacokinetics.

[4]  W. Alexander,et al.  Intrathyroidal iodide binding rates and plasma methimazole concentrations in hyperthyroid patients on small doses of carbimazole. , 1981, British journal of clinical pharmacology.

[5]  F. Karlsson,et al.  STUDIES OF THYROID HORMONE AND METHIMAZOLE LEVELS IN PATIENTS WITH GRAVES' DISEASE ON A STANDARDIZED ANTI‐THYROID DRUG REGIMEN , 1981, Clinical endocrinology.

[6]  F. Maloof,et al.  Studies of propylthiouracil using a newly developed radioimmunoassay. , 1981, The Journal of clinical endocrinology and metabolism.

[7]  G. Skellern,et al.  The metabolism of [2-14C]methimazole in the rat. , 1981, Xenobiotica; the fate of foreign compounds in biological systems.

[8]  J. Kieffer,et al.  Induction of breast cancer by nitrosomethylurea in rats of the Buffalo strain: frequent association with thyroid disease. , 1980, Endocrinology.

[9]  B. Lindström,et al.  Determination of methimazole in plasma using gas chromatography--mass spectrometry after extractive alkylation. , 1980, Journal of chromatography.

[10]  K. Johansen,et al.  PROPYLTHIOURACIL IN HUMAN MILK Revision of a Dogma , 1980, The Lancet.

[11]  G. Skellern,et al.  The pharmacokinetics of methimazole in pregnant patients after oral administration of carbimazole. , 1980, British journal of clinical pharmacology.

[12]  D. Mclarty,et al.  The pharmacokinetics of methimazole after oral administration of carbimazole and methimazole, in hyperthyroid patients. , 1980, British journal of clinical pharmacology.

[13]  A. Taurog,et al.  Mechanism of action of thioureylene antithyroid drugs: factors affecting intrathyroidal metabolism of propylthiouracil and methimazole in rats. , 1978, Endocrinology.

[14]  W. Alexander,et al.  Effects of Chronic Treatment of Intact and Hypophysectomized Rats with Thyroid-Stimulating Hormone on the Metabolism of [35S]Methimazole and [36S]Propylthiouracil , 1978 .

[15]  J. Kieffer,et al.  The irreversible inactivation of thyroid peroxidase by methylmercaptoimidazole, thiouracil, and propylthiouracil in vitro and its relationship to in vivo findings. , 1978, Endocrinology.

[16]  R. A. Neal,et al.  Metabolism of methimazole by rat liver cytochrome P-450-containing monoxygenases. , 1978, Drug metabolism and disposition: the biological fate of chemicals.

[17]  D. Stevenson,et al.  Measurement of methimazole in human plasma using gas-liquid chromatography. , 1978, Journal of chromatography.

[18]  G. Skellern,et al.  The uptake of [35S]methimazole by sheep thyroid slices in vitro. , 1978, Biochemical pharmacology.

[19]  R. Lindsay,et al.  Glucuronide conjugation of 6-n-propyl-2-thiouracil and other antithyroid drugs by guinea pig liver microsomes in vitro. , 1977, Biochemical pharmacology.

[20]  D. Mclarty,et al.  Identification of 3-methyl-2-thiohydantoin, a metabolite of carbimazole, in man. , 1977, Xenobiotica; the fate of foreign compounds in biological systems.

[21]  J. Stenlake,et al.  Improved method for the determination of methimazole in plasma by high-performance liquid chromatography. , 1976, Journal of chromatography.

[22]  A. Taurog,et al.  The mechanism of action of the thioureylene antithyroid drugs. , 1976, Endocrinology.

[23]  J. Kieffer,et al.  Pituitary-thyroid axis in neonatal and adult rats: comparison of the sexes. , 1976, Endocrinology.

[24]  W. Alexander,et al.  Relation between thyroid iodine content and the accumulation and oxidation of [35-S] Methimazole in the rat. , 1975, Endocrinology.

[25]  H. Aboul‐Enein,et al.  Enzymatic S-methylation of 6-n-propyl-2-thiouracil and other antithyroid drugs. , 1975, Biochemical pharmacology.

[26]  C. Shively,et al.  Altered plasma half‐lives of antipyrine, propylthiouracil, and methimazole in thyroid dysfunction , 1975, Clinical pharmacology and therapeutics.

[27]  H. Vorherr.  Drug excretion in breast milk. , 1974, Postgraduate medicine.

[28]  W. Alexander,et al.  Repeated administration of 35S-methimazole: pattern of accumulation and oxidation by the rat thyroid. , 1974, Endocrinology.

[29]  D. Mclarty,et al.  Plasma concentrations of methimazole, a metabolite of carbimazole, in hyperthyroid patients. , 1974, British journal of clinical pharmacology.

[30]  K. Gautvik,et al.  Thyrotropin-releasing hormone is not the sole physiologic mediator of prolactin release during suckling. , 1974, The New England journal of medicine.

[31]  U. Zor,et al.  Radioimmunological assay of prostaglandin synthetase activity. , 1973, Prostaglandins.

[32]  J. Stenlake,et al.  The absorption, distribution, excretion and metabolism of (2- 14 C)methimazole in rat. , 1973, Xenobiotica; the fate of foreign compounds in biological systems.

[33]  D. Sitar,et al.  Methimazole: absorption, metabolism and excretion in the albino rat. , 1973, The Journal of pharmacology and experimental therapeutics.

[34]  T. Lemarchand-Béraud,et al.  Thyrotropin secretion and metabolism in rats during propylthiouracil treatment. , 1973, Endocrinology.

[35]  W. Alexander,et al.  The thyroid accumulation, oxidation and metabolic fate of 35 S-methimazole in the rat. , 1972, Endocrinology.

[36]  H. Gavras,et al.  Biliary excretion of 35 S-labelled propylthiouracil, methimazole and carbimazole in untreated and pentobarbitone pretreated rats. , 1972, Biochemical pharmacology.

[37]  T. Smitherman,et al.  Methimazole: its absorption and excretion in man and tissue distribution in rats. , 1971, The Journal of clinical endocrinology and metabolism.

[38]  T. Gallagher,et al.  Metabolism of 35S-labelled Antithyroid Drugs in Man , 1969, British medical journal.

[39]  J. Scott,et al.  A new route to the imidazole-2-thiones from 2-thiohydantoins. Implications in the study of ergothioneine. , 1968, The Biochemical journal.

[40]  J. Pierce,et al.  Human thyroglobulin: studies on the native and S-carboxymethylated protein. , 1965, Biochimica et biophysica acta.

[41]  J. Benotti,et al.  Determination of total iodine in urine, stool, diets, and tissue. , 1965, Clinical chemistry.

[42]  K. Woeber,et al.  ANTITHYROID EFFECT OF NONCALORIGENIC CONGENERS OF SALICYLATE, WITH OBSERVATIONS ON THE INFLUENCE OF SERUM PROTEINS ON THE POTENCY OF ANTITHYROID AGENTS. , 1965, Endocrinology.

[43]  E. B. Astwood,et al.  1-Methyl-2-mercaptoimidazole; an antithyroid compound highly active in man. , 1949, Endocrinology.

[44]  R. H. Williams,et al.  THIOURACIL. ITS ABSORPTION, DISTRIBUTION, AND EXCRETION. , 1944, The Journal of clinical investigation.